A Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid and Islet Cell Cancer
Study Status
Closed to Enrollment
Study Description
This phase II trial is studying the side effects of giving temsirolimus together with bevacizumab and to see how well it works in treating patients with locally advanced, recurrent, metastatic, or progressive endometrial cancer, ovarian epithelial cancer, liver cancer, islet cell cancer, or carcinoid tumor.
Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab may kill more tumor cells.
Disease Status and/or Stage
Locally Advanced, Recurrant or Metastatic disease
Sponsor
Mayo Clinic, National Cancer Institute
Key Eligibility
- Men and women age 18 and over
- Diagnosed with:
- Endometrial Cancer
- Gastrointestinal Carinoid Tumor
- Islet Cell Tumor
- Liver Cancer
- Lung Cancer
- Ovarian Cancer
- Endometrial Cancer
- Locally advanced, recurrent or metastatic disease
- Additional eligibility criteria to be discussed when you contact the study team
Principal Investigator
Contact
- Michael Ehrie, RN
- (212) 746-6738
- [email protected]
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Erica Bersin
Tel: (646) 962-8232
[email protected]